Cargando…

Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study

An emerging issue in neuroimaging is to assess the diagnostic reliability of PET and its application in clinical practice. We aimed at assessing the accuracy of brain FDG-PET in discriminating patients with MCI due to Alzheimer's disease and healthy controls. Sixty-two patients with amnestic MC...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagani, M., De Carli, F., Morbelli, S., Öberg, J., Chincarini, A., Frisoni, G.B., Galluzzi, S., Perneczky, R., Drzezga, A., van Berckel, B.N.M., Ossenkoppele, R., Didic, M., Guedj, E., Brugnolo, A., Picco, A., Arnaldi, D., Ferrara, M., Buschiazzo, A., Sambuceti, G., Nobili, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299956/
https://www.ncbi.nlm.nih.gov/pubmed/25610765
http://dx.doi.org/10.1016/j.nicl.2014.11.007
_version_ 1782353456055451648
author Pagani, M.
De Carli, F.
Morbelli, S.
Öberg, J.
Chincarini, A.
Frisoni, G.B.
Galluzzi, S.
Perneczky, R.
Drzezga, A.
van Berckel, B.N.M.
Ossenkoppele, R.
Didic, M.
Guedj, E.
Brugnolo, A.
Picco, A.
Arnaldi, D.
Ferrara, M.
Buschiazzo, A.
Sambuceti, G.
Nobili, F.
author_facet Pagani, M.
De Carli, F.
Morbelli, S.
Öberg, J.
Chincarini, A.
Frisoni, G.B.
Galluzzi, S.
Perneczky, R.
Drzezga, A.
van Berckel, B.N.M.
Ossenkoppele, R.
Didic, M.
Guedj, E.
Brugnolo, A.
Picco, A.
Arnaldi, D.
Ferrara, M.
Buschiazzo, A.
Sambuceti, G.
Nobili, F.
author_sort Pagani, M.
collection PubMed
description An emerging issue in neuroimaging is to assess the diagnostic reliability of PET and its application in clinical practice. We aimed at assessing the accuracy of brain FDG-PET in discriminating patients with MCI due to Alzheimer's disease and healthy controls. Sixty-two patients with amnestic MCI and 109 healthy subjects recruited in five centers of the European AD Consortium were enrolled. Group analysis was performed by SPM8 to confirm metabolic differences. Discriminant analyses were then carried out using the mean FDG uptake values normalized to the cerebellum computed in 45 anatomical volumes of interest (VOIs) in each hemisphere (90 VOIs) as defined in the Automated Anatomical Labeling (AAL) Atlas and on 12 meta-VOIs, bilaterally, obtained merging VOIs with similar anatomo-functional characteristics. Further, asymmetry indexes were calculated for both datasets. Accuracy of discrimination by a Support Vector Machine (SVM) and the AAL VOIs was tested against a validated method (PALZ). At the voxel level SMP8 showed a relative hypometabolism in the bilateral precuneus, and posterior cingulate, temporo-parietal and frontal cortices. Discriminant analysis classified subjects with an accuracy ranging between .91 and .83 as a function of data organization. The best values were obtained from a subset of 6 meta-VOIs plus 6 asymmetry values reaching an area under the ROC curve of .947, significantly larger than the one obtained by the PALZ score. High accuracy in discriminating MCI converters from healthy controls was reached by a non-linear classifier based on SVM applied on predefined anatomo-functional regions and inter-hemispheric asymmetries. Data pre-processing was automated and simplified by an in-house created Matlab-based script encouraging its routine clinical use. Further validation toward nonconverter MCI patients with adequately long follow-up is needed.
format Online
Article
Text
id pubmed-4299956
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-42999562015-01-21 Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study Pagani, M. De Carli, F. Morbelli, S. Öberg, J. Chincarini, A. Frisoni, G.B. Galluzzi, S. Perneczky, R. Drzezga, A. van Berckel, B.N.M. Ossenkoppele, R. Didic, M. Guedj, E. Brugnolo, A. Picco, A. Arnaldi, D. Ferrara, M. Buschiazzo, A. Sambuceti, G. Nobili, F. Neuroimage Clin Regular Article An emerging issue in neuroimaging is to assess the diagnostic reliability of PET and its application in clinical practice. We aimed at assessing the accuracy of brain FDG-PET in discriminating patients with MCI due to Alzheimer's disease and healthy controls. Sixty-two patients with amnestic MCI and 109 healthy subjects recruited in five centers of the European AD Consortium were enrolled. Group analysis was performed by SPM8 to confirm metabolic differences. Discriminant analyses were then carried out using the mean FDG uptake values normalized to the cerebellum computed in 45 anatomical volumes of interest (VOIs) in each hemisphere (90 VOIs) as defined in the Automated Anatomical Labeling (AAL) Atlas and on 12 meta-VOIs, bilaterally, obtained merging VOIs with similar anatomo-functional characteristics. Further, asymmetry indexes were calculated for both datasets. Accuracy of discrimination by a Support Vector Machine (SVM) and the AAL VOIs was tested against a validated method (PALZ). At the voxel level SMP8 showed a relative hypometabolism in the bilateral precuneus, and posterior cingulate, temporo-parietal and frontal cortices. Discriminant analysis classified subjects with an accuracy ranging between .91 and .83 as a function of data organization. The best values were obtained from a subset of 6 meta-VOIs plus 6 asymmetry values reaching an area under the ROC curve of .947, significantly larger than the one obtained by the PALZ score. High accuracy in discriminating MCI converters from healthy controls was reached by a non-linear classifier based on SVM applied on predefined anatomo-functional regions and inter-hemispheric asymmetries. Data pre-processing was automated and simplified by an in-house created Matlab-based script encouraging its routine clinical use. Further validation toward nonconverter MCI patients with adequately long follow-up is needed. Elsevier 2014-11-18 /pmc/articles/PMC4299956/ /pubmed/25610765 http://dx.doi.org/10.1016/j.nicl.2014.11.007 Text en © 2014 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Regular Article
Pagani, M.
De Carli, F.
Morbelli, S.
Öberg, J.
Chincarini, A.
Frisoni, G.B.
Galluzzi, S.
Perneczky, R.
Drzezga, A.
van Berckel, B.N.M.
Ossenkoppele, R.
Didic, M.
Guedj, E.
Brugnolo, A.
Picco, A.
Arnaldi, D.
Ferrara, M.
Buschiazzo, A.
Sambuceti, G.
Nobili, F.
Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study
title Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study
title_full Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study
title_fullStr Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study
title_full_unstemmed Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study
title_short Volume of interest-based [(18)F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study
title_sort volume of interest-based [(18)f]fluorodeoxyglucose pet discriminates mci converting to alzheimer's disease from healthy controls. a european alzheimer's disease consortium (eadc) study
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299956/
https://www.ncbi.nlm.nih.gov/pubmed/25610765
http://dx.doi.org/10.1016/j.nicl.2014.11.007
work_keys_str_mv AT paganim volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT decarlif volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT morbellis volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT obergj volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT chincarinia volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT frisonigb volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT galluzzis volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT perneczkyr volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT drzezgaa volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT vanberckelbnm volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT ossenkoppeler volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT didicm volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT guedje volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT brugnoloa volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT piccoa volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT arnaldid volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT ferraram volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT buschiazzoa volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT sambucetig volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy
AT nobilif volumeofinterestbased18ffluorodeoxyglucosepetdiscriminatesmciconvertingtoalzheimersdiseasefromhealthycontrolsaeuropeanalzheimersdiseaseconsortiumeadcstudy